Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01696968 · ClinicalTrials.gov registry record · NA

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

A NA study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
NA
Development phase
154,901
Enrollment target
1
Study location

NCT01696968: Active NA study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).

NCT01696968 is a NA study of Lung Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 154,901 participants, above the 967-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (15919% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01696968, a NA study of Lung Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
154,901 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for lung cancer.

Primary Outcome

Lung cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Conditions Studied

Interventions

  • PROCEDURE X-Ray Imaging
  • OTHER Screening Questionnaire Administration

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 154,901 participants
Start Date 1993-11-16
Est. Completion 2026-03-25
Phase NA
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT01696968 still lists

NCT01696968 is an interventional study that assigns participants to a tested intervention. Its 154,901 participants enrollment target places it among the larger protocols in the corpus, above the 967-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (15919% higher).

The record links to 1 condition, with Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which X-Ray Imaging is the first listed.

NCT01696968 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01696968 about?

NCT01696968 is a clinical study titled "Screening for Lung Cancer in Older Patients (PLCO Screening Trial)". This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for lung cancer.

What is the current status of trial NCT01696968?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 154,901 participants. The study started on 1993-11-16. Estimated completion is 2026-03-25.

What conditions does trial NCT01696968 study?

This clinical trial studies the following conditions: Lung Carcinoma.

What interventions are being tested in trial NCT01696968?

The interventions under investigation include: X-Ray Imaging (PROCEDURE), Screening Questionnaire Administration (OTHER).

Who is sponsoring clinical trial NCT01696968?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01696968 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01696968's enrollment target sits among peer trials

154,901 1st of 38 higher than 38 of 38 other Lung Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06917339 · 156,000 participants

    Retrospective Analyses of TrakStar Database

  • NCT06232551 · 152,000 participants · NA

    Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

  • NCT05994482 · 130,000 participants

    Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

  • NCT06090578 · 180,000 participants · NA

    TabCAT Brain Health Assessment in Primary Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01696968, the US trial registry maintained by the National Library of Medicine. NCT01696968 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.